A5036945601- Cystic Fibrosis Research Advances
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Neonatal Respiratory Health Research
- Tracheal and airway disorders
- Musculoskeletal pain and rehabilitation
- Respiratory Support and Mechanisms
- Respiratory and Cough-Related Research
- Oral and Maxillofacial Pathology
- Kidney Stones and Urolithiasis Treatments
- Cardiovascular and exercise physiology
- Airway Management and Intubation Techniques
- Pediatric health and respiratory diseases
- Pediatric Urology and Nephrology Studies
- Oral Health Pathology and Treatment
- Delphi Technique in Research
- Asthma and respiratory diseases
- Lung Cancer Diagnosis and Treatment
- Inhalation and Respiratory Drug Delivery
- Urological Disorders and Treatments
Ospedale San Carlo
1999-2022
Medizinische Hochschule Hannover
2021
University of Insubria
2018-2019
Hospital Universitario Virgen de la Arrixaca
2017
Elexacaftor/tezacaftor/ivacaftor (ETI) is the newest cystic fibrosis transmembrane conductance regulator (
The sit-to-stand (STS) test is a feasible tool for measuring peripheral muscle strength of the lower limbs. There evidence increasing use STS tests in patients with COPD. We sought to evaluate subjects COPD minimum clinically important difference 30-s after pulmonary rehabilitation.Stable undergoing and 6-min walk (6MWT) before rehabilitation were included. Responsiveness was determined by change results (Δ STS) rehabilitation. evaluated using an anchor-based method.96 moderate-to-severe At...
We evaluated the effectiveness and safety of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in three subjects carrying Phe508del/unknown CFTR genotype. An ex vivo analysis on nasal epithelial cells (NEC) indicated a significant improvement gating activity after treatment. Three patients were enrolled an ELX/TEZ/IVA managed-access program, including with highest percent predicted Forced Expiratory Volume 1st second (ppFEV1) < 40 preceding 3 months. Data collected at baseline 8, 12 24 weeks...
Abstract Sleep‐related oxygen desaturation has been described in patients with cystic fibrosis (CF). Thus we studied the effects of inhaled Salmeterol xinafoate, a long‐acting beta‐2 agonist, on transcutaneous oxyhemoglobin saturation sleeping, stable CF patients. Patients (n = 23) were divided into responders and nonresponders to agonists, based an albuterol challenge during daytime testing, then they received salmeterol before sleep, double‐blind crossover design. Overnight measurements...
The sit-to-stand test (STST) is a feasible alternative for measuring peripheral muscle strength of the lower limbs. Our aim was to evaluate, in Chronic Obstructive Pulmonary Disease (COPD) patients, minimal clinically important difference (MCID) 30-second STST (30-STST) after pulmonary rehabilitation (PR). Stable COPD inpatients undergoing 30-STST and 6-minute walk (6MWT) before PR were included. Responsiveness determined by pre-to-post (∆) evaluation 30-STST. MCID evaluated using an...
OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is associated with a higher risk of infections.This not only negatively affects patients' quality life but also increases social and health costs.Hence, there need for an effective rehabilitative treatment including airway clearance.The aim this pilot study was to evaluate the efficacy new tool bronchial clearance based on expiratory flow accelerator (EFA) technology compared positive pressure (PEP) treatment. MATERIALS AND...
Abstract Elexacaftor / tezacaftor ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane regulator (CFTR) modulator. It known to be efficacious in stable patients with severe pneumopathy, but there are few data concerning its effectiveness during acute exacerbations. We here describe use woman CF and respiratory failure.